LaunXP biomedical

Our strategies focus on developing NCE (new chemical entities) for anti-cancer and researching a new or better way of patients. Now we have several patents for 505(b)(1) and 505(b)(2). We developed an anti-cancer rapid screen platform by reposition in new indications for FDA-approved drugs, which we obtained 505(b)(2) patents already. These advantages of those 505(b)(2) drugs would be the First-in-class medication in chemotherapy, shortening the development process and saving significant investment. Furthermore, we developed the new formulation for drug delivery system, which called VLPs. The outcome of VLPs would make LaunXP more comprehensive in drug development area

Launxp biomedical operates in the Biotechnology research industry.

Launxp biomedical's revenue is 11m - 100m

Launxp biomedical has 11 - 50 employees.